In a cohort of patients with advanced bladder cancer receiving immunotherapy, we were also able to divide the patients into two molecular subclasses: DDR1 patients with low expression of DDR-related genes and DDR2 patients with high expression of DDR-related genes (Figure 2E). This evidence concerns the gene DDR2 and urinary bladder carcinoma.